Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Oricula Therapeutics Logo
Oricula Therapeutics Growth Score
4
CB Rank
656733
Heat Score
1
Oricula Therapeutics develops and commercializes drugs to prevent hearing loss.
Founded
obfuscation
PrivateGrant Wa Keeney, Kansas, United States1-10 oricularx.com
Biotechnology
Health Care
Therapeutics
Overview

Oricula Therapeutics
Total Funding
obfuscation
Growth Score
4
Heat Score
1

Total Funding
obfuscation
obfuscation
Grant raised
obfuscation
Growth Score4
-1 pts
in past quarter
Heat Score 1
-8 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Oricula Therapeutics

CB Rank
656733
Oricula Therapeutics develops and commercializes drugs to prevent hearing loss.
Founded
obfuscation
PrivateGrant Wa Keeney, Kansas, United States1-10 oricularx.com
Biotechnology
Health Care
Therapeutics

Funding Rounds

Grant
OBF
in
obfuscation
Seed
OBF
in
obfuscation
Pre-Seed
OBF
in
obfuscation

Key People

Details

Legal Name Oricula Therapeutics LLC
Operating Status Active
Company Type For Profit
Founders  Graham Johnson, Vince Groppi
About the Company
Oricula Therapeutics develops and commercializes drugs to prevent hearing loss. The company was incorporated in 2013 and is based in Seattle, Washington.
Phone Number 2063227526
Contact Email gleser@oricularx.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

ORC-13661
An oral medication designed to prevent hearing loss during aminoglycoside antibiotic therapy, currently in Phase 2 clinical trials.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant
obfuscation
Grant - Oricula Therapeutics Logo
Grant - Oricula Therapeutics
—
obfuscation
— Grant

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 3 Contacts 2

Employee Profiles

News

News and Press

News•Feb 2, 2016
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

384

IT Spend

$67.7KThis year, Oricula Therapeutics is projected to spend $67.7K on IT, according to Aberdeen.

Actively Used Products

11Oricula Therapeutics uses 11 technology products and services including HTML5, Vimeo, and  Google Fonts, according to G2 Stack.

Active Website Tech Count

4Oricula Therapeutics is actively using 4 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  Euro.
Sub-Organizations
Frequently Asked Questions

Where is Oricula Therapeutics's headquarters? Oricula Therapeutics is located in Wa Keeney, Kansas, United States.Who invested in Oricula Therapeutics? Oricula Therapeutics is funded by University of Washington.When was the last funding round for Oricula Therapeutics? Oricula Therapeutics closed its last funding round on
obfuscation
from a Grant round.Who are Oricula Therapeutics's competitors? Alternatives and possible competitors to Oricula Therapeutics may include Sensorion, Fennec Pharmaceuticals, and  Decibel Therapeutics.How much funding has Oricula Therapeutics raised to date? Oricula Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|